Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Zura Bio Limited - Class A Ordinary shares
(NQ:
ZURA
)
3.250
-0.040 (-1.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Zura Bio Limited - Class A Ordinary shares
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants
August 12, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants
August 09, 2024
From
Zura Bio Limited
Via
Business Wire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
August 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
July 12, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
June 14, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
June 06, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
June 03, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Announces Participation in June Investor Conferences
May 29, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
April 18, 2024
From
Zura Bio
Via
Business Wire
Zura Bio Announces Robert Lisicki as CEO and Director
April 08, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
March 28, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Announces Participation at March Conferences
March 04, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Announces Participation at February Investor Conferences
February 02, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
January 08, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit
January 03, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok
December 04, 2023
From
Zura Bio Limited
Via
Business Wire
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors
November 14, 2023
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 13, 2023
From
Zura Bio Limited
Via
Business Wire
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute
September 12, 2023
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 14, 2023
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Join the Russell 2000® and Russell 3000® Indexes
June 23, 2023
From
Zura Bio Limited
Via
Business Wire
Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist
June 06, 2023
From
Zura Bio
Via
Business Wire
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases
April 27, 2023
From
Zura Bio Limited
Via
Business Wire
Zura Bio Announces Appointment of Chief Scientific Officer
April 14, 2023
From
Zura Bio Limited
Via
Business Wire
Zura Bio Limited Announces Share Redemptions and Lock-up Agreement
March 27, 2023
From
Zura Bio
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.